• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    India Geographic Atrophy GA Market

    ID: MRFR/HC/49914-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    India Geographic Atrophy GA Market Research Report By Age Group (Above 60 Years, Above 75 Years), By Diagnosis (Fundus Autofluorescence, Optical Coherence Tomography Angiography, Multifocal Electroretinography) and By Therapeutic Agents Clinical Phase (Late-Stage, Phase II, Phase I, Pre-Clinical Stage, Discovery Candidates)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    India Geographic Atrophy (GA) Market Research Report - Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    India Geographic Atrophy GA Market Summary

    The India Geographic Atrophy market is projected to grow from 1.35 USD Billion in 2024 to 3 USD Billion by 2035, indicating a robust growth trajectory.

    Key Market Trends & Highlights

    India Geographic Atrophy GA Key Trends and Highlights

    • The market is expected to expand at a compound annual growth rate of 7.53 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 3 USD Billion, reflecting increasing demand for treatment options.
    • In 2024, the market is valued at 1.35 USD Billion, highlighting a significant starting point for future growth.
    • Growing adoption of advanced therapeutic technologies due to rising prevalence of age-related macular degeneration is a major market driver.

    Market Size & Forecast

    2024 Market Size 1.35 (USD Billion)
    2035 Market Size 3 (USD Billion)
    CAGR (2025-2035) 7.53%

    Major Players

    Santen Pharmaceutical, Aurion Biotech, Croma Pharma, Ophthotech, Novartis, Allergan, Neurotech, Bayer, Kowa Company, Roche, Bausch + Lomb, Kiorpharma, Grey Wolf Therapeutics, Regeneron Pharmaceuticals, Alcon

    India Geographic Atrophy GA Market Trends

    The India Geographic Atrophy (GA) market is experiencing significant trends driven by the growing elderly population, as India has one of the largest demographics of senior citizens globally. This demographic shift leads to an increased prevalence of age-related macular degeneration (AMD), which includes geographic atrophy, thereby creating a substantial need for effective treatment options. The government’s initiatives towards enhancing eye care infrastructure and promoting awareness about eye diseases further support the market's development.

    Key market drivers include advancements in research and development for new therapies targeting geographic atrophy.Pharmaceutical companies are increasingly investing in innovative treatment modalities, including gene therapies and injectable medications, which represent a shift in how eye diseases are treated. Furthermore, partnerships between governmental health agencies and private sector players are creating synergies that facilitate better access to cutting-edge treatments for patients across the country.

    Opportunities in the India market can be captured by focusing on telemedicine and digital health solutions that provide remote consultation and monitoring for patients suffering from geographic atrophy. The rise of health tech platforms presents a chance to improve patient engagement and adherence to treatment regimens.Similarly, educational initiatives aimed at healthcare professionals about the importance of early diagnosis can stimulate market growth.

    Trends in recent times show an uptick in clinical trials and research focused on geographic atrophy within India, supported by a strong regulatory framework. This active participation in research indicates the market's potential resulting in the introduction of newer therapies. Overall, these developments align with the broader goal of enhancing vision care as part of India's healthcare agenda.

    India Geographic Atrophy GA Market Drivers

    Market Segment Insights

    Get more detailed insights about India Geographic Atrophy (GA) Market Research Report - Forecast to 2035

    Regional Insights

    Key Players and Competitive Insights

    The India Geographic Atrophy GA Market is currently undergoing significant developments as it grapples with the challenges posed by age-related macular degeneration, a leading cause of vision loss. This market is characterized by a blend of established players and emerging companies focusing on innovative therapeutic solutions. The competitive landscape is becoming increasingly dynamic, driven by the necessity for effective treatment options and the growing patient population affected by this condition. Companies are investing in research and development to bring forth novel therapies while also exploring collaborations and partnerships.

    The regulatory environment, along with market access hurdles and reimbursement frameworks, plays a pivotal role in shaping the strategies of firms operating in this space. Understanding the competitive insights within this market is essential for companies to navigate the complexities and identify potential opportunities.Santen Pharmaceutical has made a notable mark in the India Geographic Atrophy GA Market by leveraging its extensive expertise in ophthalmic pharmaceuticals. The company is recognized for its commitment to improving patient outcomes through innovative treatments.

    Santen's strengths lie in its dedicated focus on research and development, enabling it to stay at the forefront of advancements in therapies targeting geographic atrophy. The company has established a strong presence in the Indian market, thanks in part to its strategic collaborations with local healthcare providers and stakeholders. By tailoring its product offerings to meet the specific needs of the Indian population, Santen has been able to create a solid foundation of trust and reliability among healthcare professionals, enhancing its competitive edge in this evolving landscape.

    Aurion Biotech is also a significant player in the India Geographic Atrophy GA Market, focusing on ground-breaking therapeutic solutions aimed at retinal diseases. Known for its research-driven approach, Aurion Biotech has developed several key products specifically designed to address the unmet needs of patients suffering from geographic atrophy. The company's strengths include its focus on innovation and its commitment to advancing the understanding of retinal health through extensive clinical studies. In India, Aurion Biotech enjoys a favorable market presence due to its relationships with ophthalmologists and healthcare facilities, allowing for better distribution and access to its therapies.

    The company's strategic initiatives, including potential mergers and acquisitions, aim to bolster its market position and expand its portfolio of solutions tailored for the Indian demographic. This combination of innovative product development and strategic market engagement enhances Aurion Biotech's competitiveness in the Indian market for geographic atrophy treatment.

    Key Companies in the India Geographic Atrophy GA Market market include

    Industry Developments

    The India Geographic Atrophy (GA) Market is witnessing significant developments, particularly with companies such as Santen Pharmaceutical and Novartis, are advancing their research initiatives for treatments targeting this condition. Current affairs indicate that Aurion Biotech has made strides in clinical trials for its GA therapies, further indicating a burgeoning interest in the sector. An important merger was noted in August 2023 when Neurotech acquired a minority stake in a research venture with Croma Pharma, aiming to innovate therapeutic solutions for GA.

    In terms of market dynamics, Bausch + Lomb and Allergan are actively enhancing their product pipelines to capture a larger share of the growing market, propelled by an increasing population with retina-related disorders in India. The Indian government's efforts to improve healthcare infrastructure are also catalyzing advancements in the GA market, facilitating better access to innovative treatments. Over the past two years, significant investments have poured into research and development by Bayer and Regeneron Pharmaceuticals, reflecting an ongoing commitment to address the unmet medical needs of GA patients.

    Market Segmentation

    Geographic Atrophy GA Market Age Group Outlook

    • Above 60 Years
    • Above 75 Years

    Geographic Atrophy GA Market Diagnosis Outlook

    • Fundus Autofluorescence
    • Optical Coherence Tomography Angiography
    • Multifocal Electroretinography

    Geographic Atrophy GA Market Therapeutic Agents Clinical Phase Outlook

    • Late-Stage
    • Phase II
    • Phase I
    • Pre-Clinical Stage
    • Discovery Candidates

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 1.35(USD Billion)
    MARKET SIZE 2024 1.75(USD Billion)
    MARKET SIZE 2035 3.0(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 5.022% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Santen Pharmaceutical, Aurion Biotech, Croma Pharma, Ophthotech, Novartis, Allergan, Neurotech, Bayer, Kowa Company, Roche, Bausch + Lomb, Kiorpharma, Grey Wolf Therapeutics, Regeneron Pharmaceuticals, Alcon
    SEGMENTS COVERED Age Group, Diagnosis, Therapeutic Agents Clinical Phase
    KEY MARKET OPPORTUNITIES Rising elderly population prevalence, Increased awareness and diagnosis, Innovative treatment development, Growing healthcare infrastructure, Investment in clinical trials and research
    KEY MARKET DYNAMICS increasing elderly population, rising prevalence of GA, advancements in treatment options, growing awareness and diagnosis, supportive regulatory environment
    COUNTRIES COVERED India

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the expected market size of the India Geographic Atrophy GA Market by 2035?

    The India Geographic Atrophy GA Market is expected to be valued at 3.0 USD Billion by 2035.

    What was the market size of the India Geographic Atrophy GA Market in 2024?

    The market size of the India Geographic Atrophy GA Market in 2024 was valued at 1.75 USD Billion.

    What is the expected compound annual growth rate (CAGR) for the India Geographic Atrophy GA Market from 2025 to 2035?

    The expected CAGR for the India Geographic Atrophy GA Market from 2025 to 2035 is 5.022%.

    Which age group contributes significantly to the India Geographic Atrophy GA Market?

    The age group of Above 60 Years significantly contributes to the India Geographic Atrophy GA Market.

    What is the projected market size for the Above 60 Years age group in 2035?

    The projected market size for the Above 60 Years age group in 2035 is 1.8 USD Billion.

    What is the projected market size for the Above 75 Years age group in 2035?

    The projected market size for the Above 75 Years age group in 2035 is 1.2 USD Billion.

    Who are some major players in the India Geographic Atrophy GA Market?

    Major players in the market include Santen Pharmaceutical, Aurion Biotech, Croma Pharma, and Novartis.

    What are the key growth drivers for the India Geographic Atrophy GA Market?

    Key growth drivers include the increasing elderly population and advancements in treatment options.

    What challenges does the India Geographic Atrophy GA Market face?

    Challenges in the market include high treatment costs and limited awareness about Geographic Atrophy.

    What is the anticipated market growth rate for the India Geographic Atrophy GA Market?

    The anticipated market growth rate for the India Geographic Atrophy GA Market is projected to be steady at 5.022% CAGR through 2035.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. India Geographic Atrophy GA Market, BY Age Group (USD Billion)
    45. Above 60 Years
    46. Above 75 Years
    47. India Geographic Atrophy GA Market, BY Diagnosis (USD Billion)
    48. Fundus Autofluorescence
    49. Optical Coherence Tomography Angiography
    50. Multifocal Electroretinography
    51. India Geographic Atrophy GA Market, BY Therapeutic Agents Clinical Phase (USD Billion)
    52. Late-Stage
    53. Phase II
    54. Phase I
    55. Pre-Clinical Stage
    56. Discovery Candidates
    57. Competitive Landscape
    58. Overview
    59. Competitive Analysis
    60. Market share Analysis
    61. Major Growth Strategy in the Geographic Atrophy GA Market
    62. Competitive Benchmarking
    63. Leading Players in Terms of Number of Developments in the Geographic Atrophy GA Market
    64. Key developments and growth strategies
    65. New Product Launch/Service Deployment
    66. Merger & Acquisitions
    67. Joint Ventures
    68. Major Players Financial Matrix
    69. Sales and Operating Income
    70. Major Players R&D Expenditure. 2023
    71. Company Profiles
    72. Santen Pharmaceutical
    73. Financial Overview
    74. Products Offered
    75. Key Developments
    76. SWOT Analysis
    77. Key Strategies
    78. Aurion Biotech
    79. Financial Overview
    80. Products Offered
    81. Key Developments
    82. SWOT Analysis
    83. Key Strategies
    84. Croma Pharma
    85. Financial Overview
    86. Products Offered
    87. Key Developments
    88. SWOT Analysis
    89. Key Strategies
    90. Ophthotech
    91. Financial Overview
    92. Products Offered
    93. Key Developments
    94. SWOT Analysis
    95. Key Strategies
    96. Novartis
    97. Financial Overview
    98. Products Offered
    99. Key Developments
    100. SWOT Analysis
    101. Key Strategies
    102. Allergan
    103. Financial Overview
    104. Products Offered
    105. Key Developments
    106. SWOT Analysis
    107. Key Strategies
    108. Neurotech
    109. Financial Overview
    110. Products Offered
    111. Key Developments
    112. SWOT Analysis
    113. Key Strategies
    114. Bayer
    115. Financial Overview
    116. Products Offered
    117. Key Developments
    118. SWOT Analysis
    119. Key Strategies
    120. Kowa Company
    121. Financial Overview
    122. Products Offered
    123. Key Developments
    124. SWOT Analysis
    125. Key Strategies
    126. Roche
    127. Financial Overview
    128. Products Offered
    129. Key Developments
    130. SWOT Analysis
    131. Key Strategies
    132. Bausch + Lomb
    133. Financial Overview
    134. Products Offered
    135. Key Developments
    136. SWOT Analysis
    137. Key Strategies
    138. Kiorpharma
    139. Financial Overview
    140. Products Offered
    141. Key Developments
    142. SWOT Analysis
    143. Key Strategies
    144. Grey Wolf Therapeutics
    145. Financial Overview
    146. Products Offered
    147. Key Developments
    148. SWOT Analysis
    149. Key Strategies
    150. Regeneron Pharmaceuticals
    151. Financial Overview
    152. Products Offered
    153. Key Developments
    154. SWOT Analysis
    155. Key Strategies
    156. Alcon
    157. Financial Overview
    158. Products Offered
    159. Key Developments
    160. SWOT Analysis
    161. Key Strategies
    162. References
    163. Related Reports
    164. India Geographic Atrophy GA Market SIZE ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD Billions)
    165. India Geographic Atrophy GA Market SIZE ESTIMATES & FORECAST, BY DIAGNOSIS, 2019-2035 (USD Billions)
    166. India Geographic Atrophy GA Market SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AGENTS CLINICAL PHASE, 2019-2035 (USD Billions)
    167. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    168. ACQUISITION/PARTNERSHIP
    169. MARKET SYNOPSIS
    170. INDIA GEOGRAPHIC ATROPHY GA MARKET ANALYSIS BY AGE GROUP
    171. INDIA GEOGRAPHIC ATROPHY GA MARKET ANALYSIS BY DIAGNOSIS
    172. INDIA GEOGRAPHIC ATROPHY GA MARKET ANALYSIS BY THERAPEUTIC AGENTS CLINICAL PHASE
    173. KEY BUYING CRITERIA OF GEOGRAPHIC ATROPHY GA MARKET
    174. RESEARCH PROCESS OF MRFR
    175. DRO ANALYSIS OF GEOGRAPHIC ATROPHY GA MARKET
    176. DRIVERS IMPACT ANALYSIS: GEOGRAPHIC ATROPHY GA MARKET
    177. RESTRAINTS IMPACT ANALYSIS: GEOGRAPHIC ATROPHY GA MARKET
    178. SUPPLY / VALUE CHAIN: GEOGRAPHIC ATROPHY GA MARKET
    179. GEOGRAPHIC ATROPHY GA MARKET, BY AGE GROUP, 2025 (% SHARE)
    180. GEOGRAPHIC ATROPHY GA MARKET, BY AGE GROUP, 2019 TO 2035 (USD Billions)
    181. GEOGRAPHIC ATROPHY GA MARKET, BY DIAGNOSIS, 2025 (% SHARE)
    182. GEOGRAPHIC ATROPHY GA MARKET, BY DIAGNOSIS, 2019 TO 2035 (USD Billions)
    183. GEOGRAPHIC ATROPHY GA MARKET, BY THERAPEUTIC AGENTS CLINICAL PHASE, 2025 (% SHARE)
    184. GEOGRAPHIC ATROPHY GA MARKET, BY THERAPEUTIC AGENTS CLINICAL PHASE, 2019 TO 2035 (USD Billions)
    185. BENCHMARKING OF MAJOR COMPETITORS

    India Geographic Atrophy GA Market Segmentation

     

     

     

    • Geographic Atrophy GA Market By Age Group (USD Billion, 2019-2035)

      • Above 60 Years
      • Above 75 Years

     

    • Geographic Atrophy GA Market By Diagnosis (USD Billion, 2019-2035)

      • Fundus Autofluorescence
      • Optical Coherence Tomography Angiography
      • Multifocal Electroretinography

     

    • Geographic Atrophy GA Market By Therapeutic Agents Clinical Phase (USD Billion, 2019-2035)

      • Late-Stage
      • Phase II
      • Phase I
      • Pre-Clinical Stage
      • Discovery Candidates

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials